Glenmark gains with arm getting approval from USFDA for Sevelamer Hydrochloride Tablets by admin- Monday, February 11th, 2019 04:23:21 PM
Glenmark Pharmaceuticals is currently trading at Rs. 619.60, up by way of five.15 factors or 0.84% from its preceding ultimate of Rs. 614.45 at the BSE.
The scrip opened at Rs. 614.Fifty five and has touched a high and coffee of Rs. 623.50 and Rs. 614.00 respectively. So a ways 4450 shares were traded on the counter.
The BSE organization ‘A’ inventory of face cost Rs. 1 has touched a 52 week high of Rs. 711.Fifty five on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.
Last one week excessive and low of the scrip stood at Rs. 664.45 and Rs. 612.00 respectively. The cutting-edge marketplace cap of the corporation is Rs. 17337.Eighty two crore.
The promoters maintaining within the organization stood at forty six.Fifty four%, even as Institutions and Non-Institutions held 39.20% and 14.26% respectively.
Glenmark Pharmaceuticals – subsidiary — Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by way of the US Food & Drug Administration (USFDA) for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg, a frequent version of Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation.
According to IQVIA income records for the 12 month period ending December 2018, the Renagel Tablets, four hundred mg and 800 mg marketplace carried out annual sales of about $102.1 million.
The organisation’s current portfolio includes 149 merchandise authorized for distribution within the US market area and 53 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark maintains to pick out and discover outside improvement partnerships to complement and boost up the growth of its existing pipeline and portfolio.